Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations.

MLA

Corianò, Matilde, et al. “Role of Hb to RDW Ratio in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Immunotherapy Combinations.” Immunotherapy, vol. 17, no. 1, Jan. 2025, pp. 25–35. EBSCOhost, https://doi.org/10.1080/1750743X.2025.2452145.

APA

Corianò, M., Lazzarin, A., Maffezzoli, M., Santoni, M., Mazzaschi, G., Rodella, S., Simoni, N., Lai, E., Maruzzo, M., Basso, U., Bimbatti, D., Iacovelli, R., Anghelone, A., Fiala, O., Rebuzzi, S. E., Fornarini, G., Lolli, C., Massari, F., Rosellini, M., … Buti, S. (2025). Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations. Immunotherapy, 17(1), 25–35. https://doi.org/10.1080/1750743X.2025.2452145

Chicago

Corianò, Matilde, Alessandro Lazzarin, Michele Maffezzoli, Matteo Santoni, Giulia Mazzaschi, Sara Rodella, Nicola Simoni, et al. 2025. “Role of Hb to RDW Ratio in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Immunotherapy Combinations.” Immunotherapy 17 (1): 25–35. doi:10.1080/1750743X.2025.2452145.